Metelimumab
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. Touted as a drug of the future,[1] Metelimumab was dropped from further development in favour of GC-1008,[2] which is currently being developed by Genzyme.[3]
History
CAT-192 was isolated by Cambridge Antibody Technology using its phage display technology. In 2000, Cambridge Antibody Technology signed a collaborative deal with Genzyme to further develop TGF beta antibodies.[4][5]
In 2004, Cambridge Antibody Technology and Genzyme revealed that Phase I/II trials of CAT-192 for scleroderma showed the human anti-TGF-Beta1 monoclonal antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.[6]
Initial trials targeted the skin condition scleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of GC-1008,[2] which is currently being developed by Genzyme.[3]
References
- ^ http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=860002&p_IsPs=N
- ^ a b http://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-569445.html
- ^ a b http://www.genzymeoncology.com/onc/research/onc_p_research.asp
- ^ http://prnwire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-28-2000/0001324438&EDATE=
- ^ http://www.drugdiscoveryonline.com/article.mvc/Cambridge-Antibody-Genzyme-to-collaborate-on-0001?VNETCOOKIE=NO
- ^ http://goliath.ecnext.com/coms2/gi_0199-693661/CAT-192-is-safe-but.html
- ^ http://www.genzymeoncology.com/onc/clinical/trialdetailresults.asp?nct=NCT00043706
|
|
Intracellular
(initiation) |
|
|
Intracellular
(reception) |
|
|
Extracellular |
|
|
Serum target
(noncellular)
|
|
|
Cellular target
|
CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) • CD4 (Clenoliximab, Keliximab, Zanolimumab) • CD11a (Efalizumab) • CD18 (Erlizumab) • CD20 (Afutuzumab, Rituximab, Ocrelizumab, Pascolizumab) • CD23 (Gomiliximab, Lumiliximab) • CD40 (Teneliximab, Toralizumab) • CD62L/L-selectin (Aselizumab) • CD80 (Galiximab) • CD147/Basigin (Gavilimomab) • CD154 (Ruplizumab)
BLyS (Belimumab) • CTLA-4 (Ipilimumab, Tremelimumab) • CAT (Bertilimumab, Lerdelimumab, Metelimumab) • Integrin (Natalizumab) • Interleukin-6 receptor (Tocilizumab) • LFA-1 (Odulimomab)
IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab)
T-lymphocyte ( Zolimomab aritox)
|
|
Unsorted
|
Atorolimumab, Cedelizumab, Fontolizumab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab
|
|
|
|
|
|
|
|
|
|
|
|
cell/phys/auag/auab/comp, igrc
|
|
|
|
|
|
|
|
Immune system ("-l(i[m])-") |
Human ("-limu-")
|
|
|
Mouse ("-limo-")
|
|
|
|
|
|
|
|
|
Chimeric + humanized
("-lixizu-")
|
|
|
|
Interleukin ("-k(i[n])-") |
Human ("-kinu-")
|
|
|
Humanized ("-kizu-", "-kinzu-")
|
|
|
|
Inflammatory lesions ("-les-") |
|
|
|
cell/phys/auag/auab/comp, igrc
|
|
|
|
|
|